nach oben

Erschienen in:

01.08.2011 | Original Article

Polymorphisms of Tumor Necrosis Factor-Alpha and Hepatocellular Carcinoma Risk: A HuGE Systematic Review and Meta-Analysis

verfasst von: Yonggang Wei, Fei Liu, Bo Li, Xi Chen, Yu Ma, Lvnan Yan, Tianfu Wen, Mingqing Xu, Wentao Wang, Jiayin Yang

Erschienen in: Digestive Diseases and Sciences | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Studies investigating the associations between tumor necrosis factor-alpha (TNFA) polymorphisms and hepatocellular carcinoma (HCC) risk report conflicting results. We conducted a meta-analysis to assess the association between TNFA gene TNFA-308(G/A), TNFA-238(G/A), TNFA-863(C/A), TNFA-857(C/T), TNFA-1031 (T/C) polymorphisms and HCC susceptibility.

Methods

Two investigators independently searched the Medline, Embase, CNKI, and Chinese Biomedicine Database. Summary odds ratios (ORs) and 95% confidence intervals (95% CIs) for TNFA polymorphisms and HCC were calculated in a fixed-effects model (the Mantel–Haenszel method) and a random-effects model (the DerSimonian and Laird method) when appropriate.

Results

This meta-analysis included 17 case–control studies, which included 2,357 HCC cases and 3,161 controls. Overall, the variant genotypes AA/AG of -308G/A were associated with a significantly increased HCC risk, when compared with GG genotype (AA vs. GG, OR = 1.97, 95%CI = 1.01–3.83; AG vs. GG, OR = 1.88, 95%CI = 1.23–2.88; AA/AG vs. GG, OR = 1.80, 95%CI = 1.19–2.72). When stratifying for ethnicity, significantly elevated HCC risk was found among Asians. Moreover, similar results were observed between TNFA-238G/A, TNFA-863C/A polymorphisms and HCC risk among Asians (for -238G/A, AG vs. GG OR = 1.63, 95%CI = 1.17–2.26, AA/AG vs. GG OR = 1.61, 95%CI = 1.16–2.24; for -863 C/A, AC vs. CC OR = 1.72, 95%CI = 1.03–2.88, AA/AC vs. CC OR = 1.71, 95%CI = 1.02–2.86), while no associations were observed between TNFA-857C/T, TNFA-1031T/C polymorphisms and HCC susceptibility.

Conclusions

This meta-analysis shows that TNFA-308G/A, TNFA-238G/A and TNFA-863C/A polymorphisms may be associated with HCC among Asians. TNFA-857C/T and TNFA-1031T/C polymorphisms were not detected to be related to the risk for HCC.

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRef

Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030–3044.PubMedCrossRef

Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol. 2005;3:27.PubMedCrossRef

Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48:1312–1327.PubMedCrossRef

Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients. Hepatology. 1995;21:650–655.PubMedCrossRef

Tarao K, Rino Y, Ohkawa S, et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer. 1999;86:589–595.PubMedCrossRef

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867.PubMedCrossRef

Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci. 2006;97:439–447.PubMedCrossRef

Hajeer AH, Hutchinson IV. Influence of TNF alpha gene polymorphisms on TNF alpha production and disease. Hum Immunol. 2001;62:1191–1199.PubMedCrossRef

10.

Hajeer AH, Hutchinson IV. TNF-alpha gene polymorphism: Clinical and biological implications. Microsc Res Tech. 2000;50:216–228.PubMedCrossRef

11.

Anderson GM, Nakada MT, DeWitte M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol. 2004;4:314–320.PubMedCrossRef

12.

Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997;34:391–399.PubMedCrossRef

13.

Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA. 1997;94:3195–3199.PubMedCrossRef

14.

Wilson AG, di Giovine FS, Blakemore AI, Duff GW. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet. 1992;1:353.PubMedCrossRef

15.

Higuchi T, Seki N, Kamizono S, et al. Polymorphism of the 5’-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens. 1998;51:605–612.PubMedCrossRef

16.

Soga Y, Nishimura F, Ohyama H, Maeda H, Takashiba S, Murayama Y. Tumor necrosis factor-alpha gene (TNF-alpha)-1031/-863, -857 single-nucleotide polymorphisms (SNPs) are associated with severe adult periodontitis in Japanese. J Clin Periodontol. 2003;30:524–531.PubMedCrossRef

17.

Kaijzel EL, Bayley JP, van Krugten MV, et al. Allele-specific quantification of tumor necrosis factor alpha (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals. Genes Immun. 2001;2:135–144.PubMedCrossRef

18.

Uglialoro AM, Turbay D, Pesavento PA, et al. Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promoter. Tissue Antigens. 1998;52:359–367.PubMedCrossRef

19.

Mestiri S, Bouaouina N, Ahmed SB, et al. Genetic variation in the tumor necrosis factor-a promoter region and in the stress protein hsp70–2: Susceptibility and prognostic implications in breast carcinoma. Cancer. 2001;91:672–678.PubMedCrossRef

20.

Warzocha K, Ribeiro P, Bienvenu J, et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin’s lymphoma outcome. Blood. 1998;91:3574–3581.PubMed

21.

Oh BR, Sasaki M, Perinchery G, et al. Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-a (TNF-a) gene in patients with prostate cancer. J Urol. 2000;163:1584–1587.PubMedCrossRef

22.

Sasaki M, Nakajima K, Perinchery G, et al. Frequent genotype changes at -308 of the human tumor necrosis factor-alpha promoter region in human uterine endometrial cancer. Oncol Rep. 2000;7:369–373.PubMed

23.

Machado JC, Figueiredo C, Canedo P, et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology. 2003;125:364–371.PubMedCrossRef

24.

Qin H, Liu B, Shi T, Liu Y, Sun Y, Ma Y. Tumour necrosis factor-alpha polymorphisms and hepatocellular carcinoma: A meta-analysis. J Int Med Res. 2010;38:760–768.PubMed

25.

Yang Y, Luo C, Feng R, Bi S. The TNF-α, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: A meta-analysis. J Cancer Res Clin Oncol. 2010; doi:10.1007/s00432-010-0959-8.

26.

Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283:2008–2012.PubMedCrossRef

27.

White DL, Li D, Nurgalieva Z, El-Serag HB. Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and meta-analysis. Am J Epidemiol. 2008;167:377–389.PubMedCrossRef

28.

Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis: Methods for quantitative synthesis in medicine. 2nd ed. New York, NY: Oxford University Press; 2000.

29.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.PubMedCrossRef

30.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–748.PubMed

31.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.PubMedCrossRef

32.

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–1101.PubMedCrossRef

33.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.PubMed

34.

Song SF, Gao YH, Gao YH, Chen SD, Chen SD. Interaction of TNF-α-308 and environmental risk factors in primary liver cancer. J Guangdong Pharm College. 2009;25:196–201. [Article in Chinese].

35.

Huang HL, Huang HL, Xie JS, Xie JS, Huang ZS, Zhao QZ. The relationship of polymorphism of tumor necrosis factor-α gene promoter -238G/A with primary hepatic carcinoma in patients. Prog Anat Sci. 2007;13:11–13. [Article in Chinese].

36.

Qiu B. Association study of gene polymorphisms and expression of TNF-α, TAP with hepatocellular carcinoma. Available at: http://dlib3.edu.cnki.net/kns50/detail.aspx?QueryID=17&CurRec=1. 2010 June 1 [Article in Chinese].

37.

Niro GA, Fontana R, Gioffreda D, et al. Tumor necrosis factor gene polymorphisms and clearance or progression of hepatitis B virus infection. Liver Int. 2005;25:1175–1181.PubMedCrossRef

38.

Ben-Ari Z, Mor E, Papo O, et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol. 2003;98:144–150.PubMedCrossRef

39.

Jung KW, Ha E, Yu GI, et al. TNF alpha promoter polymorphism is a risk factor for susceptibility in hepatocellular carcinoma in Korean population. Clin Chim Acta. 2009;407:16–19.PubMedCrossRef

40.

Jeng JE, Tsai HR, Chuang LY, et al. Independent and additive interactive effects among tumor necrosis factor-alpha polymorphisms, substance use habits, and chronic hepatitis B and hepatitis C virus infection on risk for hepatocellular carcinoma. Medicine (Baltimore). 2009;88:349–357.CrossRef

41.

Akkiz H, Bayram S, Bekar A, et al. G-308A TNF-alpha polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: Case-control study. Cancer Epidemiol. 2009;33:261–264.PubMedCrossRef

42.

Ognjanovic S, Yuan JM, Chaptman AK, Fan Y, Yu MC. Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA. Carcinogenesis. 2009;30:758–762.PubMedCrossRef

43.

Sakamoto T, Higaki Y, Hara M, et al. Interaction between interleukin-1beta -31T/C gene polymorphism and drinking and smoking habits on the risk of hepatocellular carcinoma among Japanese. Cancer Lett. 2008;271:98–104.PubMedCrossRef

44.

Kummee P, Tangkijvanich P, Poovorawan Y, Hirankarn N. Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepat. 2007;14:841–848.PubMed

45.

Jeng JE, Tsai JF, Chuang LY, et al. Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia. 2007;9:987–992.PubMedCrossRef

46.

Chen CC, Yang SY, Liu CJ, et al. Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma. Int J Epidemiol. 2005;34:1310–1318.PubMedCrossRef

47.

Migita K, Miyazoe S, Maeda Y, et al. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection—association between TGF-beta1 polymorphisms and hepatocellular carcinoma. J Hepatol. 2005;42:505–510.PubMedCrossRef

48.

Ho SY, Wang YJ, Chen HL, et al. Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the -308 tumor necrosis factor-alpha promoter gene. Cancer Causes Control. 2004;15:657–663.PubMedCrossRef

49.

Heneghan MA, Johnson PJ, Clare M, Ho S, Harrison PM, Donaldson PT. Frequency and nature of cytokine gene polymorphisms in hepatocellular carcinoma in Hong Kong Chinese. Int J Gastrointest Cancer. 2003;34:19–26.PubMedCrossRef

50.

Wang Y, Kato N, Hoshida Y, et al. Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology. 2003;37:65–71.PubMedCrossRef

51.

Zhu ZZ, Cong WM. Roles of hepatitis B virus and hepatitis C virus in hepato-carcinogenesis. Zhonghua Ganzangbing Zazhi. 2003;11:574–576.PubMed

52.

Kuper H, Tzonou A, Kaklamani E, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer. 2000;85:498–502.PubMedCrossRef

53.

Chen CJ, Wang LY, Lu SN, et al. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology. 1996;24:38–42.PubMedCrossRef

54.

Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 2005;436:946–952.PubMedCrossRef

55.

El Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160:3227–3230.PubMedCrossRef

56.

Yu MW, Yang SY, Chiu YH, et al. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology. 1999;29:697–702.PubMedCrossRef

57.

Feo F, Frau M, Tomasi ML, et al. Genetic and epigenetic control of molecular alterations in hepatocellular carcinoma. Exp Biol Med (Maywood). 2009;234:726–736.CrossRef

58.

Dragani TA. Risk of HCC: Genetic heterogeneity and complex genetics. J Hepatol. 2010;52:252–257.PubMedCrossRef

59.

Ezzikouri S, El Feydi AE, Benazzouz M, et al. Single nucleotide polymorphism in DNMT3B promoter and its association with hepatocellular carcinoma in a Moroccan population. Infect Genet Evol. 2009;9:877–881.PubMedCrossRef

60.

Kim YJ, Lee HS. Genetic epidemiological study on single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic HBV infection. Korean J Hepatol. 2009;15:7–14.PubMedCrossRef

61.

Ioannidis JP, Ntzani EE, Trikalinos TA, et al. Replication validity of genetic association studies. Nat Genet. 2001;29:306–309.PubMedCrossRef

62.

Munafò M. Replication validity of genetic association studies of smoking behavior: What can meta-analytic techniques offer? Nicotine Tob Res. 2004;6:381–382.PubMedCrossRef

Titel: Polymorphisms of Tumor Necrosis Factor-Alpha and Hepatocellular Carcinoma Risk: A HuGE Systematic Review and Meta-Analysis
verfasst von: Yonggang Wei
Fei Liu
Bo Li
Xi Chen
Yu Ma
Lvnan Yan
Tianfu Wen
Mingqing Xu
Wentao Wang
Jiayin Yang
Publikationsdatum: 01.08.2011
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 8/2011
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-011-1617-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Polymorphisms of Tumor Necrosis Factor-Alpha and Hepatocellular Carcinoma Risk: A HuGE Systematic Review and Meta-Analysis